American Well Q2 Review: Hold Rating Maintained Amid DHA Renewal Concerns

American Well (AMWL) reported strong Q2 2025 revenue growth and improved cost control, enhancing EBITDA and cash flow, buoyed by a strategic shift towards higher-margin software. However, these gains are tempered by a downward revision in guidance, primarily due to uncertainties surrounding a short Defense Health Agency (DHA) contract extension and program exclusions, which raise concerns about long-term revenue stability. Consequently, the analyst maintains a 'Hold' rating, citing persistent contract and profitability risks despite new client acquisitions and product launches.

Analysis

American Well Corporation (AMWL) presented a bifurcated outlook in its Q2 2025 report, demonstrating strong current operational execution offset by significant forward-looking uncertainty. On one hand, the company reported enhanced key financial metrics, including robust revenue growth and effective cost controls which improved its EBITDA and cash flow outlook. This performance is supported by a strategic pivot towards higher-margin software revenue, the launch of its Amwell Navigate platform, and a new client win with Florida Blue. However, these positive developments are overshadowed by a downward revision of its full-year guidance. This revision stems directly from a short-term renewal of its contract with the Defense Health Agency (DHA) and other program exclusions, raising material concerns about the long-term stability and reliability of this key revenue stream. Furthermore, while cost reductions are currently bolstering profitability, there is an associated risk that excessive cuts could undermine future growth by hampering critical investments in R&D and marketing.

Key Decisions for Investors

• Given the conflicting signals of strong current performance against significant contract uncertainty, maintaining a neutral or 'Hold' position on AMWL may be prudent until there is more clarity on long-term revenue streams.
• Investors should closely monitor all developments related to the Defense Health Agency (DHA) contract, as its renewal status is the primary driver of the current downward guidance and a key risk to future earnings.
• Scrutinize the company's operating expenses in subsequent quarters to assess if cost-cutting measures are negatively impacting R&D and marketing, which could compromise long-term competitive positioning and growth.
• Evaluate the pace and margin contribution of the ongoing shift to software-based revenue to determine if it can successfully mitigate the volatility and risk associated with large-scale contracts.